Další formáty:
BibTeX
LaTeX
RIS
@article{870390,
author = {Rektor, Ivan and Babic, Tomislav and Boothmann, Bernard and Polívka, Jiří and Boroojerdi, Babak and Randerath, Olaf},
article_number = {4},
doi = {http://dx.doi.org/10.1097/WNF.0b013e31819a689f},
keywords = {dopamine agonist; dose escalation; Parkinson disease; rotigotine transdermal patch},
language = {eng},
issn = {0362-5664},
journal = {Clinical Neuropharmacology},
title = {High Doses of Rotigotine Transdermal Patch: Results of an Open-Label, Dose-Escalation Trial in Patients With Advanced-Stage, Idiopathic Parkinson Disease},
volume = {32},
year = {2009}
}
TY - JOUR
ID - 870390
AU - Rektor, Ivan - Babic, Tomislav - Boothmann, Bernard - Polívka, Jiří - Boroojerdi, Babak - Randerath, Olaf
PY - 2009
TI - High Doses of Rotigotine Transdermal Patch: Results of an Open-Label, Dose-Escalation Trial in Patients With Advanced-Stage, Idiopathic Parkinson Disease
JF - Clinical Neuropharmacology
VL - 32
IS - 4
SP - 193-198
EP - 193-198
SN - 03625664
KW - dopamine agonist
KW - dose escalation
KW - Parkinson disease
KW - rotigotine transdermal patch
N2 - Objective: The objective of the study was to determine the maximal achievable dose of rotigotine by assessing the tolerability of escalating doses of rotigotine transdermal patch in patients with advanced-stage Parkinson disease. Methods: Thirty-four patients aged 30 years or older oil a stable dose of L-dopa with all off time of at least 2.5 h/d were randomized to 2-titration schemes. The patients started on a dosage of 4 mg/24 h and received an incremental dosage of 4 mg/24 h per week: in the fast-titration group and 2 mg/24 h per week in the slow-titration group to the maximal target dosage of 24 mg/24 h (patch size of 120 cm(2)). Thereafter, both groups entered a maintenance period of 42 days or longer for the rapid-titration group and 7 days or longer for the slow titration group followed by a 2-week safety follow-up period with stepwise dosage de-escalation of 4 mg/24 h for 4 days. Results: Twenty-seven patients completed the trial, of whom 24 completed without dose reduction. Twenty-six patients (76%) were titrated to the maximum target dose and thus had a maximal achievable dosage of at least 24 mg/24 h. Adverse events, generally mild or moderate, included application site reaction (12%), nausea, dyskinesia, and visual hallucinations (9% each). The mean time spent off decreased by 2 to 3 h/d. Duration of oil without dyskinesia periods increased (2 h/d). The mean total (SD) Unified Parkinson's Disease Rating Score decreased by 18.9 (14.2) in the fast-titration group and 17.8 (14.0) in the slow titration group. A shift from off to on without dyskinesias in status after waking up was observed. Conclusions: Rotigotine transdermal patch, Lip to 24 mg/24 It, was effective and well tolerated by patients with advanced-stage Parkinson disease.
ER -
REKTOR, Ivan, Tomislav BABIC, Bernard BOOTHMANN, Jiří POLÍVKA, Babak BOROOJERDI a Olaf RANDERATH. High Doses of Rotigotine Transdermal Patch: Results of an Open-Label, Dose-Escalation Trial in Patients With Advanced-Stage, Idiopathic Parkinson Disease. \textit{Clinical Neuropharmacology}. roč.~32, č.~4, s.~193-198. ISSN~0362-5664. doi:10.1097/WNF.0b013e31819a689f. 2009.
|
